This algorithm provides concise visual guidance in the form of algorithms to assist with clinical decision-making for the management of persons with type 2 diabetes mellitus and related comorbidities.

This updated guideline provides recommendations for the care and management of people with or at risk for diabetes mellitus at every stage, including prevention, diagnosis, and treatment.

Advanced diabetes technology can potentially assist persons with diabetes to achieve glycemic targets, improve quality of life, reduce burden of care, offer a personalized approach to self-management, and improve the efficiency of clinical decision-making, among other benefits. This guideline provides recommendations on the efficacy and safety of advanced diabetes technology devices for management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for implementation of this technology.

The 2020 algorithm for management of persons with type 2 diabetes includes sections on lifestyle therapy, a complications-centric model for care of persons with overweight/obesity, prediabetes, management of hypertension and dyslipidemia (risk factors for atherosclerotic cardiovascular disease), glucose control with medications, insulin therapy, and a chart summarizing the attributes of each antihyperglycemic class approved by the U.S. Food and Drug Administration through December 2019. **An updated algorithm is coming in May 2023**

This position statement presents the proceedings of conferences held by AACE in with health care professionals and community leaders that focused on improvement of diabetes care for African Americans, Latino/Hispanics, Asian Americans, and Native Americans in the United States. Based on these meetings, AACE created a diabetes care model that promotes educational, research, and clinical practice enhancements, including but not limited to the use of culturally appropriate language, nutritional messaging, health literacy, clinic infrastructure with flexible office hours, behavioral medicine, community partnerships for care delivery, technology innovation, and clinical trial recruitment and retention of ethnic minorities with the goal of improved patient outcomes.

This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application.

After careful review, AACE may endorse clinical guidance documents developed by external organizations to provide up-to-date recommendations for practice or valuable ancillary knowledge for AACE members and their teams to improve care of patients. Endorsements are reviewed and approved by AACE leadership.